Citations (77)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jiazheng Li, Can Kong, Wei Song & Tao Fu. (2023) Identification of Cuproptosis-Related Subtypes, Establishment of a Prognostic Signature and Characterization of the Tumor Microenvironment in Gastric Cancer. International Journal of General Medicine 16, pages 1631-1652.
Read now
Read now
Huan Wu, Hanchu Wang, Zhenyou Jiang & Yue Chen. (2021) Identification of Three Core Secretome Genes Associated with Immune Infiltration in High Tumor Mutation Burden Across 14 Major Solid Tumors. International Journal of General Medicine 14, pages 6755-6767.
Read now
Read now
Siyu Xia, Yun Gu, Haijian Zhang, Yuchao Fei, Yifan Cao, Hanji Fang, Jieti Wang, Chao Lin, Heng Zhang, He Li, Hongyong He, Jiejie Xu, Ruochen Li, Hao Liu & Weijuan Zhang. (2021) Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. OncoImmunology 10:1.
Read now
Read now
Xin Zhang, Yanbin Sun, Yuan Miao & Shun Xu. (2020) Immune Checkpoint Inhibitor Therapy Achieved Complete Response for Drug-Sensitive EGFR/ALK Mutation-Negative Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma with High Tumor Mutation Burden: A Case Report. OncoTargets and Therapy 13, pages 8245-8250.
Read now
Read now
Lilit Karapetyan, Jason J Luke & Diwakar Davar. (2020) Toll-Like Receptor 9 Agonists in Cancer. OncoTargets and Therapy 13, pages 10039-10060.
Read now
Read now
Katarina Hradska, Michal Kascak, Roman Hajek & Tomas Jelinek. (2020) Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. Expert Review of Hematology 13:4, pages 375-392.
Read now
Read now
Articles from other publishers (71)
Xing Huang, Yipeng Feng, Yutao Li, Hanlin Ding, Xiaochen Huang, Chen Chen, Ziru Yu, Jingyuan Zhang, Xinyu Xu, Dawei Ma, Shaorong Yu & Chen Chen. (2024) A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma. International Immunopharmacology 127, pages 111286.
Crossref
Crossref
Wenjie Zhu, Changlei Wu, Shiqi Hu, Sicheng Liu, Shimin Zhao, Dongdong Zhang, Guisheng Qiu, Xiufeng Cheng & Jun Huang. (2023) Chemokine- and chemokine receptor-based signature predicts immunotherapy response in female colorectal adenocarcinoma patients. Scientific Reports 13:1.
Crossref
Crossref
Robert T. Galvin, Sampreeti Jena, Danielle Maeser, Robert Gruener & R. Stephanie Huang. (2023) Revealing Pan-Histology Immunomodulatory Targets in Pediatric Central Nervous System Tumors. Cancers 15:22, pages 5455.
Crossref
Crossref
Jiahui Liang, Xin Wang, Jing Yang, Peng Sun, Jingjing Sun, Shengrong Cheng, Jincheng Liu, Zhiyao Ren & Min Ren. (2023) Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer. Frontiers in Immunology 14.
Crossref
Crossref
Liu Li, Kuang Tianrui, Li Chunlei, Qiu Zhendong, Chen Xiaoyan & Deng Wenhong. (2023) HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma. Aging 15:16, pages 7997-8012.
Crossref
Crossref
Chao Chen, Haozhen Liu, Yanlin Li & Jixian Liu. (2023) Association of ERCC family mutations with prognosis and immune checkpoint inhibitors response in multiple cancers. Scientific Reports 13:1.
Crossref
Crossref
Jiazheng Li, Chao Yang & Yongbin Zheng. (2023) A novel disulfidptosis and glycolysis related risk score signature for prediction of prognosis and ICI therapeutic responsiveness in colorectal cancer. Scientific Reports 13:1.
Crossref
Crossref
Yongxing Chen, Chenxin Jin, Jiaxue Cui, Yizhuo Diao, Ruiqi Wang, Rongxuan Xu, Zhihan Yao, Wei Wu & Xiaofeng Li. (2023) Single-cell sequencing and bulk RNA data reveal the tumor microenvironment infiltration characteristics of disulfidptosis related genes in breast cancer. Journal of Cancer Research and Clinical Oncology.
Crossref
Crossref
Huan Wu, Hanchu Wang & Yue Chen. (2022) Pan-cancer analysis of tumor mutation burden sensitive tumors reveals tumor-specific subtypes and hub genes related to immune infiltration. Journal of Cancer Research and Clinical Oncology 149:7, pages 2793-2804.
Crossref
Crossref
Yuqi Song, Jianzun Ma, Linan Fang, Mingbo Tang, Xinliang Gao, Dongshan Zhu & Wei Liu. (2023) Endoplasmic reticulum stress-related gene model predicts prognosis and guides therapies in lung adenocarcinoma. BMC Bioinformatics 24:1.
Crossref
Crossref
Raffaele Gaeta, Mariangela Morelli, Francesca Lessi, Chiara Maria Mazzanti, Michele Menicagli, Rodolfo Capanna, Lorenzo Andreani, Luca Coccoli, Paolo Aretini & Alessandro Franchi. (2023) Identification of New Potential Prognostic and Predictive Markers in High-Grade Osteosarcoma Using Whole Exome Sequencing. International Journal of Molecular Sciences 24:12, pages 10086.
Crossref
Crossref
Joonatan Mattila, Silja Sormunen, Nelli Heikkilä, Ilkka P. Mattila, Jari Saramäki & T. Petteri Arstila. (2023) Analysis of thymic generation of shared T‐cell receptor α repertoire associated with recognition of tumor antigens shows no preference for neoantigens over wild‐type antigens. Cancer Medicine 12:12, pages 13486-13496.
Crossref
Crossref
Yixuan Wang, Jiayin Wang, Wenfeng Fang, Xiao Xiao, Quan Wang, Jian Zhao, Jingjing Liu, Shuanying Yang, Yuqian Liu, Xin Lai & Xiaofeng Song. (2023) TMBserval: a statistical explainable learning model reveals weighted tumor mutation burden better categorizing therapeutic benefits. Frontiers in Immunology 14.
Crossref
Crossref
Guan-Zhan Liang, Xiao-Feng Wen, Yi-Wen Song, Zong-Jin Zhang, Jing Chen, Yong-Le Chen, Wei-Dong Pan, Xiao-Wen He, Tuo Hu & Zhen-Yu Xian. (2023) Construction and Validation of a Novel Prognosis Model in Colon Cancer Based on Cuproptosis-Related Long Non-Coding RNAs. Journal of Clinical Medicine 12:4, pages 1528.
Crossref
Crossref
Shengbin Pei, Pengpeng Zhang, Huilin Chen, Shuhan Zhao, Yuhan Dai, Lili Yang, Yakun Kang, Mingjie Zheng, Yiqin Xia & Hui Xie. (2023) Integrating single-cell RNA-seq and bulk RNA-seq to construct prognostic signatures to explore the role of glutamine metabolism in breast cancer. Frontiers in Endocrinology 14.
Crossref
Crossref
Huilin Xu, Dedong Cao, Dingjie Zhou, Anbing He, Wei Ge & Ximing Xu. (2023) Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis. Journal of Oncology 2023, pages 1-17.
Crossref
Crossref
Durgesh Wankhede, Sandeep Grover & Paul Hofman. (2023) The prognostic value of TMB in early-stage non-small cell lung cancer: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology 15.
Crossref
Crossref
Huilin Xu, Pingpo Ming, Zhenyu Zhao, Nan Zhao, Dingjie Zhou, Xixian Tang & Dedong Cao. (2023) Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis. Integrative Cancer Therapies 22, pages 153473542311645.
Crossref
Crossref
Xiangyu Liu, Zhenyu Liu, Ye Yan, Kai Wang, Aodi Wang, Xiongjun Ye, Liwei Wang, Wei Wei, Bao Li, Caixia Sun, Wei He, Xuehua Zhu, Zenan Liu, Jiangang Liu, Jian Lu & Jie Tian. (2023) Development of Prognostic Biomarkers by TMB-Guided WSI Analysis: A Two-Step Approach. IEEE Journal of Biomedical and Health Informatics, pages 1-9.
Crossref
Crossref
S. Voutilainen, P. Heikkilä, J. Bartkova, H. Nevanlinna, C. Blomqvist, J. Bartek & J. Mattson. (2022) Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases. BMC Cancer 22:1.
Crossref
Crossref
Jiehui Cai, Xinkang Zhang, Wanchun Xie, Zhiyang Li, Wei Liu & An Liu. (2022) Identification of a basement membrane-related gene signature for predicting prognosis and estimating the tumor immune microenvironment in breast cancer. Frontiers in Endocrinology 13.
Crossref
Crossref
Ying Shi, Mengwan Wu, Yuyang Liu, Ling Chen, Xiuwu Bian & Chuan Xu. (2022) Bottlenecks and opportunities in immunotherapy for glioma: a narrative review. Journal of Bio-X Research 5:4, pages 151-162.
Crossref
Crossref
Jing Chen, Yi-Wen Song, Guan-Zhan Liang, Zong-Jin Zhang, Xiao-Feng Wen, Rui-Bing Li, Yong-Le Chen, Wei-Dong Pan, Xiao-Wen He, Tuo Hu & Zhen-Yu Xian. (2022) A Novel m7G-Related Gene Signature Predicts the Prognosis of Colon Cancer. Cancers 14:22, pages 5527.
Crossref
Crossref
Ruby Gupta, Sachin Gupta, Bana Antonios, Bipin Ghimire, Vishal Jindal, Jaskiran Deol, Suzanna Gaikazian, Marianne Huben, Joseph Anderson, Michael Stender & Ishmael Jaiyesimi. (2022) Therapeutic landscape of advanced HER2-positive breast cancer in 2022. Medical Oncology 39:12.
Crossref
Crossref
Yixuan Wang, Xin Lai, Jiayin Wang, Ying Xu, Xuanping Zhang, Xiaoyan Zhu, Yuqian Liu, Yang Shao, Li Zhang & Wenfeng Fang. (2022) TMBcat: A multi-endpoint p-value criterion on different discrepancy metrics for superiorly inferring tumor mutation burden thresholds. Frontiers in Immunology 13.
Crossref
Crossref
Jiehui Cai, Zeqi Ji, Jinyao Wu, Lingzhi Chen, Daitian Zheng, Yaokun Chen, Xinkang Zhang, Wanchun Xie, Jieying Huang, Manqi Chen, Ru Lin, Weixun Lin, Yexi Chen & Zhiyang Li. (2022) Development and validation of a novel endoplasmic reticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer. Frontiers in Genetics 13.
Crossref
Crossref
Tao Wang, Zhijia Zhou, Xuan Wang, Liping You, Wenxuan Li, Chao Zheng, Jinghao Zhang, Lingtai Wang, Xiaoni Kong, Yueqiu Gao & Xuehua Sun. (2022) Comprehensive analysis of nine m7G-related lncRNAs as prognosis factors in tumor immune microenvironment of hepatocellular carcinoma and experimental validation. Frontiers in Genetics 13.
Crossref
Crossref
Yixuan Wang, Xin Lai, Jiayin Wang, Ying Xu, Xuanping Zhang, Xiaoyan Zhu, Yuqian Liu, Yang Shao, Li Zhang & Wenfeng Fang. (2022) A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden Threshold. Frontiers in Genetics 13.
Crossref
Crossref
Midie Xu, Jinjia Chang, Wenfeng Wang, Xin Wang, Xu Wang, Weiwei Weng, Cong Tan, Meng Zhang, Shujuan Ni, Lei Wang, Zhaohui Huang, Zhenzhong Deng, Wenhua Li, Dan Huang & Weiqi Sheng. (2022) Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Jiazheng Li, Renshen Xiang, Wei Song, Jing Wu, Can Kong & Tao Fu. (2022) A Novel Ferroptosis-Related LncRNA Pair Prognostic Signature Predicts Immune Landscapes and Treatment Responses for Gastric Cancer Patients. Frontiers in Genetics 13.
Crossref
Crossref
Yongguang Liu, Kaimei Huang, Yachao Yang, Yan Wu & Wei Gao. (2022) Prediction of Tumor Mutation Load in Colorectal Cancer Histopathological Images Based on Deep Learning. Frontiers in Oncology 12.
Crossref
Crossref
Yong Li, Yihong Liu, Yanchun Qu, Xian Chen, Xin Qu, Yongsong Ye, Xiaohua Du, Ying Cheng, Mian Xu & Haibo Zhang. (2022) Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy. Frontiers in Immunology 13.
Crossref
Crossref
Biao Ning, Yixin Liu, Miao Wang, Yi Li, Tianzi Xu & Yongchang Wei. (2022) The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Jie Zhao, Yiting Dong, Hua Bai, Jianchun Duan, Guoqiang Wang, Jiachen Xu, Jie Wang & Zhijie Wang. (2022) Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis. Journal of the National Cancer Center 2:1, pages 41-49.
Crossref
Crossref
Jacob R. Bradley & Timothy I. Cannings. (2022) Data-driven design of targeted gene panels for estimating immunotherapy biomarkers. Communications Biology 5:1.
Crossref
Crossref
舜 饶. (2022) Research Progress of Tumor Mutational Burden in Predicting Prognosis of Patients with Malignant Tumors. Advances in Clinical Medicine 12:08, pages 7000-7004.
Crossref
Crossref
Ge Yu, Han Mu, Feng Fang, Hongyuan Zhou, Huikai Li, Qiang Wu, Qingqing Xiong & Yunlong Cui. (2022) LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma. Medicine 101:26, pages e29763.
Crossref
Crossref
Shaoxing Sun, Wenjie Sun, Qingming Xiang, Chunxu Yang, Min Chen, Zijie Mei, Hui Yang, Zihang Zeng, Hong Cao, Yueli Tian, Gong Zhang & Hui Qiu. (2021) Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report. Anti-Cancer Drugs 33:1, pages e756-e759.
Crossref
Crossref
Shuo Xu, Ruixue Lai, Qian Zhao, Pandong Zhao, Ruili Zhao & Zhanjun Guo. (2021) Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Immunology 12.
Crossref
Crossref
Ya Jun Liu, Alphonse Houssou Hounye, Zheng Wang, Xiaowei Liu, Jun Yi & Min Qi. (2021) Identification and Validation of Three Autophagy-Related Long Noncoding RNAs as Prognostic Signature in Cholangiocarcinoma. Frontiers in Oncology 11.
Crossref
Crossref
He Ba, Lei Liu, Qiang Peng, Jie Chen & Yao-dong Zhu. (2021) The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer 21:1.
Crossref
Crossref
Junhun Cho, Sang Eun Yoon, Seok Jin Kim, Young Hyeh Ko & Won Seog Kim. (2021) Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing. BMC Cancer 21:1.
Crossref
Crossref
Zhao Zhang, Yongbo Yu, Pengfei Zhang, Guofeng Ma, Mingxin Zhang, Ye Liang, Wei Jiao & Haitao Niu. (2021) Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer. BMC Cancer 21:1.
Crossref
Crossref
Hong Li, Lili Liu, Tianyi Huang, Ming Jin, Zhen Zheng, Hui Zhang, Meng Ye & Kaitai Liu. (2021) Establishment of a novel ferroptosis-related lncRNA pair prognostic model in colon adenocarcinoma. Aging 13:19, pages 23072-23095.
Crossref
Crossref
Yan Li, Yiqi Ma, Zijun Wu, Fanxin Zeng, Bin Song, Yanrong Zhang, Jinxing Li, Su Lui & Min Wu. (2021) Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis. Frontiers in Immunology 12.
Crossref
Crossref
Xin Fan, YangShaobo Ou, Huijie Liu, Liangzhen Zhan, Xingrong Zhu, Mingyang Cheng, Qun Li, Dongmei Yin & Lan Liao. (2021) A Ferroptosis-Related Prognostic Signature Based on Antitumor Immunity and Tumor Protein p53 Mutation Exploration for Guiding Treatment in Patients With Head and Neck Squamous Cell Carcinoma. Frontiers in Genetics 12.
Crossref
Crossref
Li Zhong, Qing Wu, Fuchun Chen, Junjin Liu & Xianhe Xie. (2021) Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunology, Immunotherapy 70:9, pages 2559-2576.
Crossref
Crossref
Catarina Príncipe, Isabel J. Dionísio de Sousa, Hugo Prazeres, Paula Soares & Raquel T. Lima. (2021) LRP1B: A Giant Lost in Cancer Translation. Pharmaceuticals 14:9, pages 836.
Crossref
Crossref
Benita C. Y. Tse, Zoe Welham, Alexander F. Engel & Mark P. Molloy. (2021) Genomic, Microbial and Immunological Microenvironment of Colorectal Polyps. Cancers 13:14, pages 3382.
Crossref
Crossref
Rui Guan, Qiong Lyu, Anqi Lin, Junyi Liang, Weimin Ding, Manming Cao, Peng Luo & Jian Zhang. (2021) Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration. Frontiers in Oncology 11.
Crossref
Crossref
Shuier Zheng, Fenglin Wang, Jin Huang, Yan Zhou, Quanjun Yang, Guowei Qian, Chenliang Zhou, Daliu Min, Lele Song & Zan Shen. (2021) Case Report: Sequential Chemotherapy and Immunotherapy Produce Sustained Response in Osteosarcoma With High Tumor Mutational Burden. Frontiers in Endocrinology 12.
Crossref
Crossref
Lorenzo Galluzzi & Abhishek D. Garg. (2021) Immunology of Cell Death in Cancer Immunotherapy. Cells 10:5, pages 1208.
Crossref
Crossref
Yuan Qiu, Liping Liu, Haihong Yang, Hanzhang Chen, Qiuhua Deng, Dakai Xiao, Yongping Lin, Changbin Zhu, Weiwei Li, Di Shao, Wenxi Jiang, Kui Wu & Jianxing He. (2021) Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Masayo Yoshimura, Kurumi Seki, Andrey Bychkov & Junya Fukuoka. (2021) Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments. Frontiers in Oncology 11.
Crossref
Crossref
Xiaona Fan, Dan Wang, Wenjing Zhang, Jinshuang Liu, Chao Liu, Qingwei Li, Zhigang Ma, Hengzhen Li, Xin Guan, Yibing Bai, Jiani Yang, Changjie Lou, Xiaobo Li, Guangyu Wang & Zhiwei Li. (2021) Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Zhu Zeng, Biao Yang & Zhengyin Liao. (2021) Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. Frontiers in Oncology 11.
Crossref
Crossref
Dongdong Yang, Jinling Yu, Bing Han, Yue Sun, Steven Mo & Jing Hu. (2021) Long Non-coding RNA Expression Patterns in Stomach Adenocarcinoma Serve as an Indicator of Tumor Mutation Burden and Are Associated With Tumor-Infiltrating Lymphocytes and Microsatellite Instability. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Aoran Dong, Yiming Zhao, Zhihua Li & Hai Hu. (2021) PD‐L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non‐small cell lung cancer?. The Journal of Gene Medicine 23:2.
Crossref
Crossref
Ran Duan, Xiaoqin Li, Dongqiang Zeng, Xiaofeng Chen, Bo Shen, Dongqin Zhu, Liuqing Zhu, Yangyang Yu & Deqiang Wang. (2021) Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer. Frontiers in Immunology 11.
Crossref
Crossref
Dong-Yan Zhao, Xi-Zhen Sun & Shu-Kun Yao. (2021) Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer. World Journal of Gastrointestinal Oncology 13:1, pages 37-57.
Crossref
Crossref
Anastasia Mpakali & Efstratios Stratikos. (2021) The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. Cancers 13:1, pages 134.
Crossref
Crossref
Deepshi Thakral, Ritu Gupta, Ranjit Kumar Sahoo, Pramod Verma, Indresh Kumar & Sangeeta Vashishtha. (2020) Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Rui Li, Dongsheng Han, Jiping Shi, YanXi Han, Ping Tan, Rui Zhang & Jinming Li. (2020) Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1874:2, pages 188420.
Crossref
Crossref
Lorenzo Pilla, Andrea Alberti, Pierluigi Di Mauro, Maria Gemelli, Viola Cogliati, Marina Elena Cazzaniga, Paolo Bidoli & Cristina Maccalli. (2020) Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. Cancers 12:11, pages 3456.
Crossref
Crossref
Huiyi Feng & Weixi Shen. (2020) ACAA1 Is a Predictive Factor of Survival and Is Correlated With T Cell Infiltration in Non-Small Cell Lung Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Mairéad G. McNamara, Timothy Jacobs, Angela Lamarca, Richard A Hubner, Juan W Valle & Eitan Amir. (2020) Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treatment Reviews 89, pages 102084.
Crossref
Crossref
Elisabeth Smolle, Katharina Leithner & Horst Olschewski. (2019) Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations. Thoracic Cancer 11:2, pages 205-215.
Crossref
Crossref
Jong Yeob Kim, Andreas Kronbichler, Michael Eisenhut, Sung Hwi Hong, Hans J. van der Vliet, Jeonghyun Kang, Jae Il Shin & Gabriele Gamerith. (2019) Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers 11:11, pages 1798.
Crossref
Crossref
Yongfeng Wu, Jinming Xu, Chengli Du, Yihua Wu, Dajing Xia, Wang Lv & Jian Hu. (2019) The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology 9.
Crossref
Crossref
Hong Zhang, Fa Zhang, Fei Ren, Zhonglie Wang, Xiaosong Rao, Li Li, Junbo Hao, Rui Yan, Jiancheng Luo & Ming Du. (2019) Predicting Tumor Mutational Burden from Liver Cancer Pathological Images Using Convolutional Neural Network. Predicting Tumor Mutational Burden from Liver Cancer Pathological Images Using Convolutional Neural Network.
Jie Zhao, Yiting Dong, Hua Ba, Jianchun Duan, Guoqiang Wang, Jiachen Xu, Zhijie Wang & Jie Wang. (2020) The Effect of Tumor Mutation Burden on Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Comprehensive Meta-Analysis. SSRN Electronic Journal.
Crossref
Crossref